News Releases

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer